Cigna revealed that it will not cover Mylan's allergy drug EpiPen on its 2017 formulary, TheStreet reported Wednesday.
The insurer instead encouraged patients to use Impax's generic device for treating severe allergic reactions.
Mylan CEO Heather Bresch called for an assessment of the healthcare pricing model pricing model and interaction across the entire supply chain.
"If I look at five entities that go across the healthcare supply chain, all the discussion has just been around one of those five - the drug manufacturers," Bresch remarked.
Mylan faced criticism last year as the price of EpiPen rose to as much as $700 for a two-pack, according to GoodRx, compared to about $200 for a two-pack of Impax's product.
Mylan launched a generic version of EpiPen last year at a 50-percent discount, a move Bresch described as "unprecedented" and "responsible."
To read more NewsPoints articles, click here.